Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Bio-pharma Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Monoclonal Antibodies Market Performance (Volume)
  • 2.1.2 Recombinant Proteins Market Performance (Volume)
  • 2.1.3 Granulocyte-Colony Stimulating Factor (G-CSF) Market Performance (Volume)
  • 2.1.4 Interferons Market Performance (Volume)
  • 2.1.5 Recombinant Human Insulin Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Monoclonal Antibodies Market Performance (Value)
  • 2.1.2 Recombinant Proteins Market Performance (Value)
  • 2.1.3 Granulocyte-Colony Stimulating Factor (G-CSF) Market Performance (Value)
  • 2.1.4 Interferons Market Performance (Value)
  • 2.1.5 Recombinant Human Insulin Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Metabolic Disorders Market Performance (Volume)
  • 3.1.2 Oncology Market Performance (Volume)
  • 3.1.3 Neurological Disorders Market Performance (Volume)
  • 3.1.4 Cardiovascular Diseases Market Performance (Volume)
  • 3.1.5 Inflammatory and Infectious Diseases Market Performance (Volume)
  • 3.1.6 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Pfizer
  • 4.1.1 Pfizer Profiles
  • 4.1.2 Pfizer Product Information
  • 4.1.3 Pfizer Bio-pharma Business Performance
  • 4.1.4 Pfizer Bio-pharma Business Development and Market Status
• 4.2 F. Hoffmann-La Roche AG
  • 4.2.1 F. Hoffmann-La Roche AG Profiles
  • 4.2.2 F. Hoffmann-La Roche AG Product Information
  • 4.2.3 F. Hoffmann-La Roche AG Bio-pharma Business Performance
  • 4.2.4 F. Hoffmann-La Roche AG Bio-pharma Business Development and Market Status
• 4.3 Johnson & Johnson Services
  • 4.3.1 Johnson & Johnson Services Profiles
  • 4.3.2 Johnson & Johnson Services Product Information
  • 4.3.3 Johnson & Johnson Services Bio-pharma Business Performance
  • 4.3.4 Johnson & Johnson Services Bio-pharma Business Development and Market Status
• 4.4 Sanofi, Amgen
  • 4.4.1 Sanofi, Amgen Profiles
  • 4.4.2 Sanofi, Amgen Product Information
  • 4.4.3 Sanofi, Amgen Bio-pharma Business Performance
  • 4.4.4 Sanofi, Amgen Bio-pharma Business Development and Market Status
• 4.5 AbbVie
  • 4.5.1 AbbVie Profiles
  • 4.5.2 AbbVie Product Information
  • 4.5.3 AbbVie Bio-pharma Business Performance
  • 4.5.4 AbbVie Bio-pharma Business Development and Market Status
• 4.6 Merck & Co., Inc
  • 4.6.1 Merck & Co., Inc Profiles
  • 4.6.2 Merck & Co., Inc Product Information
  • 4.6.3 Merck & Co., Inc Bio-pharma Business Performance
  • 4.6.4 Merck & Co., Inc Bio-pharma Business Development and Market Status
• 4.7 Biogen Idec
  • 4.7.1 Biogen Idec Profiles
  • 4.7.2 Biogen Idec Product Information
  • 4.7.3 Biogen Idec Bio-pharma Business Performance
  • 4.7.4 Biogen Idec Bio-pharma Business Development and Market Status
• 4.8 Bayer AG
  • 4.8.1 Bayer AG Profiles
  • 4.8.2 Bayer AG Product Information
  • 4.8.3 Bayer AG Bio-pharma Business Performance
  • 4.8.4 Bayer AG Bio-pharma Business Development and Market Status
• 4.9 Eli Lilly and Company
  • 4.9.1 Eli Lilly and Company Profiles
  • 4.9.2 Eli Lilly and Company Product Information
  • 4.9.3 Eli Lilly and Company Bio-pharma Business Performance
  • 4.9.4 Eli Lilly and Company Bio-pharma Business Development and Market Status
• 4.10 Novartis AG GlaxoSmithKline Plc
  • 4.10.1 Novartis AG GlaxoSmithKline Plc Profiles
  • 4.10.2 Novartis AG GlaxoSmithKline Plc Product Information
  • 4.10.3 Novartis AG GlaxoSmithKline Plc Bio-pharma Business Performance
  • 4.10.4 Novartis AG GlaxoSmithKline Plc Bio-pharma Business Development and Market Status
• 4.11 Bristol-Myers Squibb Company
• 4.12 AstraZeneca PLC
• 4.13 Johnson & Johnson Services

5 Market Performance for Manufacturers

• 5.1 Europe Bio-pharma Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe Bio-pharma Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe Bio-pharma Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe Bio-pharma Market Performance (Sales Point)

• 7.1 Europe Bio-pharma Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe Bio-pharma Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe Bio-pharma Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe Bio-pharma Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Metabolic Disorders Industry
• 11.2 Oncology Industry
• 11.3 Neurological Disorders Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe Bio-pharma Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe Bio-pharma Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Recombinant Proteins Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Interferons Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Metabolic Disorders Sales and and Growth Rate 2019-2024
  • 12.4.3 Oncology Sales and and Growth Rate 2019-2024
  • 12.4.4 Neurological Disorders Sales and and Growth Rate 2019-2024
  • 12.4.5 Cardiovascular Diseases Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe Bio-pharma Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe Bio-pharma Gross Profit Trend 2019-2024

13 Conclusion

Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Bio-pharma for these regions, from 2012 to 2023 (forecast), including
Germany
UK
France
Russia
Benelux
Italy
Spain

Europe Bio-pharma market competition by top manufacturers/players, with Bio-pharma sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Pfizer
F. Hoffmann-La Roche AG
Johnson & Johnson Services
Sanofi, Amgen
AbbVie
Merck & Co., Inc
Biogen Idec
Bayer AG
Eli Lilly and Company
Novartis AG GlaxoSmithKline Plc
Bristol-Myers Squibb Company
AstraZeneca PLC
Abbott Laboratories

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Monoclonal Antibodies
Recombinant Proteins
Granulocyte-Colony Stimulating Factor (G-CSF)
Interferons
Recombinant Human Insulin
Erythropoietin
Vaccines
Growth Hormones
Purified Proteins
Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Bio-pharma for each application, including
Metabolic Disorders
Oncology
Neurological Disorders
Cardiovascular Diseases
Inflammatory and Infectious Diseases
Others

If you have any special requirements, please let us know and we will offer you the report as you want.